newsfilter
← Latest News
GlobeNewswire·

Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program

Finch to transfer FIN-524 program to Takeda for clinical development Finch and Takeda to continue discovery efforts targeting Crohn's disease SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "F